UAB Rx pharma Finance - revenue, profit
EBITDA margin (%)
Enjoy unlimited use
with Freemium unlimitedEBIT margin (%)
Enjoy unlimited use
with Freemium unlimited| Indicator |
|---|
| Turnover (€) |
| Sales per employee (€) |
| Profit before tax (€) |
| Net Profit (€) |
| Profit per employee (€) |
| Total profitability (%) |
| Net profitability (%) |
| Equity (€) |
| Amounts Payable And Liabilities (€) |
| Non-current Assets (€) |
| CurrentAssets (€) |
| Working capital requirement |
| Debt-to-equity ratio |
| EBITDA margin (%) |
| EBITDA (€) |
| EBIT margin (%) |
| EBIT (€) |
| 2023 |
|---|
| 23,350,098 |
| 3,113,346 |
| 593,879 |
| 516,487 |
| 68,865 |
| 5.49 |
| 2.21 |
| 3,849,480 |
| 1,260,767 |
| 4,064 |
| 5,102,887 |
| 2024 |
|---|
| 24,666,210 |
| 3,479,014 |
| 585,766 |
| 505,383 |
| 71,281 |
| 5.41 |
| 2.05 |
| 3,354,863 |
| 3,217,287 |
| 6,300 |
| 6,601,011 |
| 2025 |
|---|
| 27,574,317 |
| 3,939,188 |
| 435,265 |
| 369,263 |
| 52,752 |
| 5.09 |
| 1.34 |
| 3,724,126 |
| 2,765,330 |
| 6,357 |
| 6,467,807 |
Enjoy unlimited use
with Freemium unlimited| 2025 |
|---|
| 27,574,317 |
| 3,939,188 |
| 435,265 |
| 369,263 |
| 52,752 |
| 5.09 |
| 1.34 |
| 3,724,126 |
| 2,765,330 |
| 6,357 |
| 6,467,807 |
Enjoy unlimited use
with Freemium unlimitedTurnover (€)
2025
Turnover (€)
27,574,317 €12 % *
Sales per employee (€)
3,939,188 €13 % *
Profit before tax (€)
435,265 €-26 % *
Net Profit (€)
369,263 €-27 % *
Profit per employee (€)
52,752 €-26 % *
Total profitability (%)
5.09 %-5.91 % *
Net profitability (%)
1.34 %-34.63 % *
Equity (€)
3,724,126 €11 % *
Amounts Payable And Liabilities (€)
2,765,330 €-14 % *
Non-current Assets (€)
6,357 €1 % *
CurrentAssets (€)
6,467,807 €-2 % *
